Oisín Biotechnologies - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Oisín Biotechnologies develops genetic medicines aimed at addressing age-related diseases. Based in Seattle, they are advancing a pipeline targeting drivers of aging, including frailty, fat cell removal, and senescent cell clearance. Their non-viral Fusogenix PLV delivery platform enables broad distribution of DNA and RNA payloads with potential for safe repeat dosing. The company focuses on developing therapies that improve healthspan through targeted genetic interventions.
No recent news for this company.
No recent deals for this company.
